You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Serum Hepcidin Immunoassay: Laboratory to Marketplace

    SBC: INTRINSIC LIFESCIENCES            Topic: NIDDK

    DESCRIPTION (provided by applicant): Disorders of iron metabolism are among the most common human diseases. During the last decade, rapid progress has been made in understanding the molecular basis of iron homeostasis and its disorders. The peptide hormonehepcidin has emerged as the master regulator of iron metabolism. Dysregulation of hepcidin is the principal or contributing factor in most syste ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Serum Hepcidin Immunoassay: Laboratory to Marketplace

    SBC: INTRINSIC LIFESCIENCES            Topic: 300

    DESCRIPTION provided by applicant Disorders of iron metabolism are among the most common human diseases During the last decade rapid progress has been made in understanding the molecular basis of iron homeostasis and its disorders The peptide hormone hepcidin has emerged as the master regulator of iron metabolism Dysregulation of hepcidin is the principal or contributing factor in most syst ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. TDP-43 aggregation inhibitors for the treatment of ALS

    SBC: Aquinnah Pharmaceuticals Inc.            Topic: 105

    Abstract Amyotrophic Lateral SclerosisALSis a universally fatal neurodegenerative disease that afflicts overout of everyindividualsProtein aggregation has been implicated as a primary driving force in ALS and multiple other neurodegenerative illnessesTDPis the principle component of the protein aggregates in ALSand TDPalso stands out as the only genetically defined ALS mutant gene that is also the ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer

    SBC: PRIVO TECHNOLOGIES, LLC            Topic: NCI

    Preceding Award: NCI Award 1R44CA192875-02 Project Summary: According to the Oral Cancer Foundation, about 50,000 people in the US will be newly diagnosed with oral cancer (OC) in 2017, causing 9,700 deaths[1]. OC is a severely neglected orphan disease with a lack of significant treatment advances in 4 decades[1]. Historically, OC has been present in heavy smokers and drinkers. However, more recen ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid point of care test for Lyme serodiagnosis based on novel ultra sensitive de

    SBC: IMMUNETICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Lyme disease is the most prevalent vector borne disease in the U S with about cases per year reported by CDC and a range now covering states Early diagnosis and treatment of Lyme disease is important to prevent the disease from progressing to a systemic infection characterized by chronic arthritis carditis or neurological disorders Where a patien ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid, disposable, nucleic acid diagnostic device for multiplexed point of care f

    SBC: MESA TECH INTERNATIONAL, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Rapid and accurate identification of highly infectious and pathogenic disease is extremely important for the early forecast of outbreak risk and the effective deployment of medical and administrative countermeasures Unfortunately current diagnostics for use at the point of care POC are largely immunological assays that often lack adequate sensitivity speci ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Riluzole Prodrugs for Melanoma and ALS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: 102

    We have discovered a novel Type IIb prodrug of riluzole, trigriluzole (FC-4157, BVH-4157), which has the potential to substantially improve therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action. While riluzole has shown promising efficacy in treating melanoma in patients, trigrilluzole is andgt;20X more potent than riluzo ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a urine test for the early detection of liver cancer

    SBC: JBS SCIENCE INC            Topic: 102

    Development of a urine test for the early detection of liver cancer The need to develop an effective method for detecting liver cancer is urgent. HCC, a primary liver cancer, is the third leading cause of cancer deaths worldwide and the fastest rising cancer in US. HCC has a 5-year survival rate of less than 15%, if detected early, the survival rate can be as high as 40%. The survival rate drops s ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    Project Summary This 3-year Phase II SBIR Application focuses on advancing the lead “ultra-broad-spectrum” carbapenem (USBC) VNRX-4099, possessing an unprecedented antibacterial spectrum of activity including MRSA, Enterobacteriaceae and Pseudomonas aeruginosa, to IND filing status. The UBSC VNRX-4099 will be paired with a proprietary in-house β-lactamase inhibitor VNRX-5133 (BLI) to protect ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. An Immunoprotectant for Marburg Virus

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: R

    DESCRIPTION provided by applicant Mortality rates associated with Marburg virus MARV outbreaks range from to over MARV is included by the Centers for Disease Control and Prevention as among the Category A agents or andquot high priority agents that pose a risk to national security andquot MARV not only causes acute and terrifying disease but it is relatively stable in wet or ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government